DE102005012060A1 - Oral product for the prevention and treatment of diaper dermatitis - Google Patents
Oral product for the prevention and treatment of diaper dermatitis Download PDFInfo
- Publication number
- DE102005012060A1 DE102005012060A1 DE102005012060A DE102005012060A DE102005012060A1 DE 102005012060 A1 DE102005012060 A1 DE 102005012060A1 DE 102005012060 A DE102005012060 A DE 102005012060A DE 102005012060 A DE102005012060 A DE 102005012060A DE 102005012060 A1 DE102005012060 A1 DE 102005012060A1
- Authority
- DE
- Germany
- Prior art keywords
- oral product
- esp
- product according
- amounts
- vitamin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000013588 oral product Substances 0.000 title claims abstract description 15
- 229940023486 oral product Drugs 0.000 title claims abstract description 15
- 201000004624 Dermatitis Diseases 0.000 title claims abstract description 13
- 230000002265 prevention Effects 0.000 title claims abstract description 5
- FDJOLVPMNUYSCM-WZHZPDAFSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+3].N#[C-].N([C@@H]([C@]1(C)[N-]\C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C(\C)/C1=N/C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C\C1=N\C([C@H](C1(C)C)CCC(N)=O)=C/1C)[C@@H]2CC(N)=O)=C\1[C@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]1[C@@H](O)[C@@H](N2C3=CC(C)=C(C)C=C3N=C2)O[C@@H]1CO FDJOLVPMNUYSCM-WZHZPDAFSA-L 0.000 claims abstract description 19
- KWIUHFFTVRNATP-UHFFFAOYSA-N Betaine Natural products C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 claims abstract description 12
- 229960003237 betaine Drugs 0.000 claims abstract description 6
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 claims description 10
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 claims description 8
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 claims description 8
- 229930003779 Vitamin B12 Natural products 0.000 claims description 6
- 235000019163 vitamin B12 Nutrition 0.000 claims description 6
- 239000011715 vitamin B12 Substances 0.000 claims description 6
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 claims description 5
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 claims description 5
- 229930003471 Vitamin B2 Natural products 0.000 claims description 5
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 claims description 5
- 229960002477 riboflavin Drugs 0.000 claims description 5
- 235000019164 vitamin B2 Nutrition 0.000 claims description 5
- 239000011716 vitamin B2 Substances 0.000 claims description 5
- 235000019158 vitamin B6 Nutrition 0.000 claims description 5
- 239000011726 vitamin B6 Substances 0.000 claims description 5
- 229940011671 vitamin b6 Drugs 0.000 claims description 5
- 239000004475 Arginine Substances 0.000 claims description 4
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 claims description 4
- 229960000304 folic acid Drugs 0.000 claims description 4
- 235000019152 folic acid Nutrition 0.000 claims description 4
- 239000011724 folic acid Substances 0.000 claims description 4
- 235000013305 food Nutrition 0.000 claims description 4
- 239000011787 zinc oxide Substances 0.000 claims description 4
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims description 3
- 150000001413 amino acids Chemical class 0.000 claims description 3
- 229960002173 citrulline Drugs 0.000 claims description 3
- 229960003104 ornithine Drugs 0.000 claims description 3
- 150000003751 zinc Chemical class 0.000 claims description 3
- 239000011701 zinc Substances 0.000 claims description 3
- 229910052725 zinc Inorganic materials 0.000 claims description 3
- 239000002775 capsule Substances 0.000 claims description 2
- 239000004220 glutamic acid Substances 0.000 claims description 2
- KWIUHFFTVRNATP-UHFFFAOYSA-O N,N,N-trimethylglycinium Chemical compound C[N+](C)(C)CC(O)=O KWIUHFFTVRNATP-UHFFFAOYSA-O 0.000 abstract 1
- 239000000047 product Substances 0.000 description 17
- 206010012444 Dermatitis diaper Diseases 0.000 description 8
- 208000003105 Diaper Rash Diseases 0.000 description 8
- 239000004480 active ingredient Substances 0.000 description 8
- 239000003826 tablet Substances 0.000 description 5
- 206010012735 Diarrhoea Diseases 0.000 description 4
- 230000035876 healing Effects 0.000 description 4
- 235000008452 baby food Nutrition 0.000 description 3
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 3
- 229960001231 choline Drugs 0.000 description 3
- 230000003449 preventive effect Effects 0.000 description 3
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2
- 150000004347 all-trans-retinol derivatives Chemical class 0.000 description 2
- 229940024606 amino acid Drugs 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 230000001364 causal effect Effects 0.000 description 2
- 150000001867 cobalamins Chemical class 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- RMRCNWBMXRMIRW-BYFNXCQMSA-M cyanocobalamin Chemical compound N#C[Co+]N([C@]1([H])[C@H](CC(N)=O)[C@]\2(CCC(=O)NC[C@H](C)OP(O)(=O)OC3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)C)C/2=C(C)\C([C@H](C/2(C)C)CCC(N)=O)=N\C\2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O RMRCNWBMXRMIRW-BYFNXCQMSA-M 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 235000015203 fruit juice Nutrition 0.000 description 2
- 229960002989 glutamic acid Drugs 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- FSYKKLYZXJSNPZ-UHFFFAOYSA-N sarcosine Chemical compound C[NH2+]CC([O-])=O FSYKKLYZXJSNPZ-UHFFFAOYSA-N 0.000 description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 2
- OAJLVMGLJZXSGX-CXGXMSGESA-L (2r,3r,4s,5r)-2-(6-aminopurin-9-yl)-5-methanidyloxolane-3,4-diol;cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] 1-[3-[(4z,9z,14z)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8 Chemical compound [Co+3].O[C@@H]1[C@H](O)[C@@H]([CH2-])O[C@H]1N1C2=NC=NC(N)=C2N=C1.O([C@H]1[C@H]([C@H](O[C@@H]1CO)N1C2=CC(C)=C(C)C=C2N=C1)O)P([O-])(=O)OC(C)CNC(=O)CCC1(C)C(CC(N)=O)C2[N-]\C1=C(C)/C(C(C\1(C)C)CCC(N)=O)=N/C/1=C\C(C(C/1(CC(N)=O)C)CCC(N)=O)=N\C\1=C(C)/C1=NC2(C)C(C)(CC(N)=O)C1CCC(N)=O OAJLVMGLJZXSGX-CXGXMSGESA-L 0.000 description 1
- OAJLVMGLJZXSGX-NDSREFPTSA-L (2r,3s,4s,5r)-2-(6-aminopurin-9-yl)-5-methanidyloxolane-3,4-diol;cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12 Chemical compound [Co+3].O[C@H]1[C@H](O)[C@@H]([CH2-])O[C@H]1N1C2=NC=NC(N)=C2N=C1.C1([C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)[N-]\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O OAJLVMGLJZXSGX-NDSREFPTSA-L 0.000 description 1
- 235000021537 Beetroot Nutrition 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 1
- 229930064664 L-arginine Natural products 0.000 description 1
- 235000014852 L-arginine Nutrition 0.000 description 1
- FFDGPVCHZBVARC-UHFFFAOYSA-N N,N-dimethylglycine Chemical compound CN(C)CC(O)=O FFDGPVCHZBVARC-UHFFFAOYSA-N 0.000 description 1
- MEFKEPWMEQBLKI-AIRLBKTGSA-N S-adenosyl-L-methioninate Chemical compound O[C@@H]1[C@H](O)[C@@H](C[S+](CC[C@H](N)C([O-])=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 MEFKEPWMEQBLKI-AIRLBKTGSA-N 0.000 description 1
- 108010077895 Sarcosine Proteins 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 229960001570 ademetionine Drugs 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000003851 biochemical process Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 235000020971 citrus fruits Nutrition 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 235000000639 cyanocobalamin Nutrition 0.000 description 1
- 239000011666 cyanocobalamin Substances 0.000 description 1
- 229960002104 cyanocobalamin Drugs 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 108700003601 dimethylglycine Proteins 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000007938 effervescent tablet Substances 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 125000003929 folic acid group Chemical group 0.000 description 1
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 210000004392 genitalia Anatomy 0.000 description 1
- DQOCFCZRZOAIBN-WZHZPDAFSA-L hydroxycobalamin Chemical compound O.[Co+2].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O DQOCFCZRZOAIBN-WZHZPDAFSA-L 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 238000006317 isomerization reaction Methods 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 235000007672 methylcobalamin Nutrition 0.000 description 1
- 239000011585 methylcobalamin Substances 0.000 description 1
- JEWJRMKHSMTXPP-BYFNXCQMSA-M methylcobalamin Chemical compound C[Co+]N([C@]1([H])[C@H](CC(N)=O)[C@]\2(CCC(=O)NC[C@H](C)OP(O)(=O)OC3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)C)C/2=C(C)\C([C@H](C/2(C)C)CCC(N)=O)=N\C\2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O JEWJRMKHSMTXPP-BYFNXCQMSA-M 0.000 description 1
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 1
- 239000013586 microbial product Substances 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 235000013379 molasses Nutrition 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 230000000474 nursing effect Effects 0.000 description 1
- 235000006286 nutrient intake Nutrition 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- -1 rhodanocobalamin Chemical compound 0.000 description 1
- 229940043230 sarcosine Drugs 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000000021 stimulant Substances 0.000 description 1
- 239000001384 succinic acid Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/30—Zinc; Compounds thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/15—Vitamins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/16—Inorganic salts, minerals or trace elements
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/14—Quaternary ammonium compounds, e.g. edrophonium, choline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4415—Pyridoxine, i.e. Vitamin B6
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7135—Compounds containing heavy metals
- A61K31/714—Cobalamins, e.g. cyanocobalamin, i.e. vitamin B12
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Nutrition Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Inorganic Chemistry (AREA)
- Polymers & Plastics (AREA)
- Mycology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Dermatology (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
Oral einzunehmendes Produkt zur Vorbeugung und Behandlung von Windeldermatitis, enthaltend Cobalamin und/oder Betaine.Oral product for the prevention and treatment of diaper dermatitis containing cobalamin and / or betaine.
Description
Urin und Kot verursachen bei Kontakt mit der Haut, verstärkt durch ein Milieu unter Windelauflagen, Windeldermatitis, wie sie insb. bei Kindern im ersten Lebensjahr vorkommt, oder auch bei älteren, bettlägerigen Patienten, denen Windeln angelegt werden, wie dies bei Alzheimer-Patienten und Patienten mit anderen neurodegenerativen Erkrankungen der Fall ist. Windeldermatitis ist ein beschwerlicher Zustand, der nach wie vor mit Zinkoxid enthaltenden Wundcremes oder -salben, insb. Babywundcremes oder -salben behandelt wird.urine and faeces on contact with the skin, reinforced by a milieu under diaper pads, diaper rash, as esp. occurs in children in the first year of life, or even in older, bedridden Patients who are put on diapers, as in Alzheimer's patients and patients with other neurodegenerative diseases is. Diaper rash is a troublesome condition that still persists Wound creams or ointments containing zinc oxide, in particular baby worm creams or ointments is treated.
Zu einer Windeldermatitis kommt es oftmals ohne ersichtlichen Anlass. Zwar geht gelegentlich einer Windeldermatitis eine Diarrhöe voraus, insb. eine Diarrhöe eines Kleinkindes, ggf. auch eine Diarrhöe der stillenden Mutter, ohne dass jedoch darin ein kausaler Zusammenhang gesehen werden kann.To Diaper dermatitis often occurs without apparent cause. Although diarrhea is sometimes preceded by diaper rash, diaper rash esp. a diarrhea a toddler, possibly also a diarrhea of breastfeeding mother, without that, however, a causal relationship can be seen in it.
Bei älteren Patienten, aber auch bei Kleinkindern, liegt eine mögliche Ursache einer Windeldermatitis auch in einem zu seltenen Wechsel der Windeln. Verzehr von Fruchtsäften, insbesondere von Zitrusfrüchten, führt oft zu Windeldermatitis. Eine wissenschaftlichen Ansprüchen gerecht werdende Erklärung und eine angemessene heilende oder vorbeugende Behandlung einer Windeldermatitis gibt es jedoch nicht.In elderly patients, but also in infants, is a possible cause of diaper rash also in too rare a change of diapers. Consumption of fruit juices, in particular of citrus fruits, often leads to diaper dermatitis. A scientific claims fair expectant statement and an appropriate healing or preventive treatment for one Diaper dermatitis does not exist.
Aufgabe der Erfindung war es, ein orales Mittel zur Verhinderung, zur Linderung und Heilung von Windeldermatitis zu schaffen, wobei eine vorbeugende Behandlung im Vordergrund steht.task It was the object of the invention to provide an oral remedy for relieving and to create healing of diaper rash, being a preventive Treatment is in the foreground.
Gelöst wird diese Aufgabe durch ein Produkt, wie dies näher in den Ansprüchen gekennzeichnet ist. Ein solches Produkt enthält insb. Cobalamin, auch als Vitamin B12 bezeichnet.Is solved to accomplish this task through a product as more fully characterized in the claims is. Such a product contains especially cobalamin, also called vitamin B12.
Denn der Erfindung liegt die Erkenntnis zugrunde, dass z.B. ein Mangel an Cobalamin insb. in den hier betroffenen Hautbereichen (Anal- und Genitalbereich) die Entstehung einer Windeldermatitis begünstigt und deren Abheilung erschwert. Der gezielte Einsatz von Cobalamin zur Linderung und Heilung, insb. aber zur vorbeugenden Behandlung von Windeldermatitis ist damit Kern dieser Erfindung.Because The invention is based on the recognition that e.g. a lack Cobalamin esp. In the affected skin areas (Anal- and genital area) favors the development of diaper dermatitis and their Healing difficult. The targeted use of cobalamin for relief and healing, esp. But for the preventive treatment of diaper dermatitis is thus the core of this invention.
Unter dem Begriff Cobalamin wird dabei und im Folgenden bevorzugt Cobalamin als solches verstanden, jedoch ist auch der Einsatz von Cobalamin-Derivaten, ggf. neben Cobalamin, geeignet insb. von Cyanocobalamin, Rhodanocobalamin, Hydroxycobalamin, Methylcobalamin und/oder 5'-Desoxyadenosylcobalamin. Gemische dieser Derivate sind möglich. Produkte im Sinne der Erfindung können zusätzlich zu oder statt Vitamin B12 bzw. seinen Derivaten Betaine wie Trimethylglyzin oder Cholin, einer Vorstufe von Betain, enthalten.Under The term cobalamin is preferred and hereinafter cobalamin understood as such, but also the use of cobalamin derivatives, optionally in addition to cobalamin, suitable in particular of cyanocobalamin, rhodanocobalamin, Hydroxycobalamin, methylcobalamin and / or 5'-deoxyadenosylcobalamin. Mixtures of these Derivatives are possible. Products within the meaning of the invention may be in addition to or instead of vitamin B12 or its derivatives betaines such as trimethylglycine or choline, a precursor of betaine.
Die Einarbeitung von Cobalamin und/oder Betainen in Tabletten, Nahrungs- und Genussmittel, Gelatinekapseln usw. kann in bekannter Weise erfolgen. Die Wirkstoffe können Babynahrung zugesetzt werden und sind auch für die stillende Mutter gedacht.The Incorporation of cobalamin and / or betaines into tablets, food and stimulants, gelatin capsules, etc. can be done in a known manner. The active ingredients can Baby food and are also intended for the nursing mother.
Produkte im Sinne dieser Erfindung können zusätzlich zumindest einen Wirkstoff aus der Folsäuregruppe (Folsäure, ein Derivat oder ein Salz davon), einen Wirkstoff aus der Vitamin B6-Gruppe (Vitamin B6 oder ein Derivat davon), Zinksalze bzw. Zinkoxid, einen Wirkstoff aus der Vitamin B2-Gruppe (Vitamin B2 oder ein Derivat davon) und I-Arginin, I-Citrullin, und/oder I-Ornithin (die Aminosäuren oder Derivate davon) enthalten. Auch L-Glutaminsäure ist dafür geeignet.Products in the sense of this invention additionally at least one active ingredient from the folic acid group (folic acid, a Derivative or a salt thereof), an active ingredient of the vitamin B6 group (Vitamin B6 or a derivative thereof), zinc salts or zinc oxide, a Active ingredient from the vitamin B2 group (vitamin B2 or a derivative thereof) and I-arginine, I-citrulline, and / or I-ornithine (the amino acids or Derivatives thereof). L-glutamic acid is also suitable.
Diese Kombination erfolgt aus den causal verknüpften, biochemischen Abläufen zur Bereitstellung von Methyl-, Methylen- oder Formyl-Gruppen, insbesondere zur Synthese von S-Adenosylmethionin und zur Isomerisierung von Methylmalonsäure in Bernsteinsäure.These Combination takes place from the causal linked biochemical processes Provision of methyl, methylene or formyl groups, in particular for the synthesis of S-adenosylmethionine and for the isomerization of methylmalonic in succinic acid.
Die bevorzugten Co-Komponenten gehen einher mit der der Erfindung zugrunde liegenden Erkenntnis über die Auswirkung eines Mangel an insb. Cobalamin insb. in den hier betroffenen Hautbereichen, indem bei einem solchen Mangel die Natur sich auf einem sog. Redundandenweg selbst Abhilfe zu schaffen sucht; erfindungsgemäß gilt es, dies durch entsprechende Co-Komponenten zu unterstützen.The preferred co-components go along with that of the invention lying knowledge about the effect of a lack of esp. Cobalamin esp. in here affected areas of the skin, by such a defect nature seeks to remedy itself on a so-called Redundandenweg; According to the invention, to support this by appropriate co-components.
Der Gehalt der Produkte an Wirkstoffen gemäß obiger Aufzählung sollte sich an den empfohlenen, täglichen, alters- und geschlechtsabhängigen minimalen Referenzwerten der WHO bzw. der Gesellschaften für Ernährung orientieren ((1) Referenzwerte für die Nährstoffzufuhr, Hrsg. Deutsche, Österreichische und Schweizerische Gesellschaften für Ernährung, Verlag Umschau/Braus, Frankfurt/Main (2001)).The content of active substance products as described above should be based on the recommended, daily, age- and sex-based minimum reference levels of the WHO or the Nutritional Supplements ((1) Reference levels for nutrient intake, ed Swiss Nutrition Societies, Verlag Umschau / Braus, Frankfurt / Main (2001)).
Statt reiner Wirkstoffe können auch Extrakte aus tierischen, pflanzlichen und/oder mikrobiellen Produkten oder diese selbst ursprünglich oder modifiziert verwendet werden.Instead of pure active ingredients can also extracts from animal, vegetable and / or microbial Products or these themselves used originally or modified become.
Demnach liegt die empfohlene Tagesdosis von Vitamin B12 bei 0.4–4 Mikrogramm, der als sicher erachtete Bereich zwischen 500-1000 Mikrogramm. Auch bei einer Zufuhr von 5 Milligramm an Vitamin B12 sind Nebenwirkungen nicht beobachtet worden ((2) National Academics Press, Dietary Reference Intakes (1998)).Therefore the recommended daily dose of vitamin B12 is 0.4-4 micrograms, the safe range is between 500-1000 micrograms. Also 5 milligrams of vitamin B12 are side effects not observed (2) National Academics Press, Dietary Reference Intakes (1998)).
Bei
Folsäure
liegen die entsprechenden Daten bei 60–600 Mikrogramm bzw.
bei
800-2000 Mikrogramm,
bei Vitamin B6 bei 0.1–1.9 mg bzw. 3–50 mg,
bei
Vitamin B2 bei 1,7 mg bzw. bei 50–100 mg
bei Zink (Salze/Oxid)
1–11 mg,
bei
Cholin >30 mg,
bei
I-Arginin (semiessentielle Aminosäure vorzugsweise im Kindesalter)
~ 117 mg/kg/Tag ((3) O. Eremin, L-Arginine/Springer Verlag 1996);
der Großteil
davon wird allerdings durch Nahrung zugeführt,
bei Betainen > 125 mg.For folic acid, the corresponding data are 60-600 micrograms or
at 800-2000 micrograms,
with vitamin B6 at 0.1-1.9 mg or 3-50 mg,
for vitamin B2 at 1.7 mg or at 50-100 mg
for zinc (salts / oxide) 1-11 mg,
for choline> 30 mg,
in I-arginine (semiessential amino acid, preferably in childhood) ~ 117 mg / kg / day ((3) O. Eremin, L-Arginine / Springer Verlag 1996); however, most of it is supplied by food,
for betaines> 125 mg.
Einige Ausgestaltungen sind dabei besonders vorteilhaft. Im folgenden soll die Erfindung anhand von Ausführungsbeispielen beschrieben werden, ohne sie dadurch aber unnötig einschränken zu wollen. Die Wirkstoffe können in üblichen Grundrezepten für Tabletten (auch solche mit Retard-Wirkung), Brausetabletten, Kapseln, Sirups, Sprays u. dergl. enthalten sein, desgleichen in Babynahrung.Some Embodiments are particularly advantageous. In the following should the invention based on embodiments be described, but without wanting to restrict it unnecessarily. The active ingredients can in usual Basic recipes for Tablets (including those having a sustained-release action), effervescent tablets, capsules, Syrups, sprays, etc. the like, as well as in baby food.
Entsprechende beispielhafte Tabletten sind wie folgt zusammengesetzt: Corresponding exemplary tablets are composed as follows:
Eine Tablette für Kleinkinder sollte entsprechend dem geringeren Körpergewicht weniger Wirkstoffe enthalten ((4) Anhang, Tabelle II in (1)).A Tablet for Infants should contain fewer active ingredients corresponding to the lower body weight ((4) Annex, Table II in (1)).
Bei Reduktion des Gehaltes von Vitamin B12 sollte der Gehalt an Cholin, Betain, Dimethylglyzin und/oder Sarcosin, wobei als Betain-Quelle besonders Rote-Bete-Melasse geeignet ist (im folgenden summarisch als Betaine bezeichnet), entsprechend erhöht werden.at Reduction of the content of vitamin B12 should be the content of choline, Betaine, dimethylglycine and / or sarcosine, being the betaine source especially beetroot molasses is suitable (hereinafter referred to collectively as Betaine), accordingly elevated become.
Für eine Tagesdosis sind folgende Mengen angezeigt, wobei ein solches oral einzunehmendes Produkt die Tagesdosis abdeckt: Die Menge an Cobalamin in einem solchen oral einzunehmenden Produkt beträgt vorteilhaft 0,00001 mg–2 mg, insb. 0,0001–1,5 mg, ganz besonders 0,0002–1 mg.For a daily dose the following amounts are indicated, one such to be taken orally Product covers the daily dose: The amount of cobalamin in one such oral product is advantageously 0.00001 mg-2 mg, esp. 0.0001 to 1.5 mg, especially 0.0002-1 mg.
Die Menge an Betainen in einem solchen oral einzunehmenden Produkt beträgt vorteilhaft 0,1 mg–1000 mg, bevorzugt 0 mg–800 mg.The Amount of betaines in such a product to be taken orally is advantageous 0.1 mg-1000 mg, preferably 0 mg-800 mg.
Zusätzlich enthält ein solches Produkt vorteilhaft Folsäure, insb. in Mengen von 0,001–50 mg, bevorzugt 0,01–2 mg.In addition contains such Product beneficial folic acid, esp. in amounts of 0.001-50 mg, preferably 0.01-2 mg.
Zusätzlich enthält ein solches Produkt vorteilhaft Vitamin B6, insb. in Mengen von 0,1 mg–100 mg, bevorzugt 1 mg–70 mg.In addition contains such Product advantageous vitamin B6, especially in amounts of 0.1 mg-100 mg, preferably 1 mg-70 mg.
Zusätzlich enthält ein solches Produkt vorteilhaft Vitamin B2, insb. in Mengen von 0,1 mg–500 mg, bevorzugt 1 mg–150 mg.In addition contains such Product advantageous Vitamin B2, esp. In amounts of 0.1 mg-500 mg, preferably 1 mg-150 mg.
Zusätzlich enthält ein solches Produkt vorteilhaft I-Arginin, I-Citrullin, I-Ornithin und/oder I-Glutaminsäure in Mengen von 1 mg–3 g, vorzugsweise 100 mg–1 g.In addition contains such Product advantageous I-arginine, I-citrulline, I-ornithine and / or I-glutamic acid in amounts of 1 mg-3 g, preferably 100 mg-1 G.
Zusätzlich enthält ein solches Produkt vorteilhaft Zink in Form von Zinksalzen und/oder Zinkoxid, insb. in Mengen von 0,1 mg–100 mg, bevorzugt 1 mg–20 mg.In addition contains such Product advantageous zinc in the form of zinc salts and / or zinc oxide, esp. in amounts of 0.1 mg-100 mg, preferably 1 mg-20 mg.
Ein solches Produkt liegt vorteilhaft in Form eines oral einzunehmenden Produktes vor: Tablette, verkapselte Darreichung, Süßigkeit, Nahrungsmittel. Die Wirkstoffe können auch Babynahrung in entsprechenden Konzentrationen zugesetzt werden.One such product is advantageously in the form of an oral Product before: tablet, encapsulated administration, candy, Food. The active ingredients can Baby food can be added in appropriate concentrations.
Die Erfindung betrifft weiterhin die Verwendung eines solchen Produkts zur oralen Behandlung von Windeldermatitis, insb. aber zur Vorbeugung von Windeldermatitis.The The invention further relates to the use of such a product for the oral treatment of diaper rash, esp. But for the prevention from diaper rash.
Bei der erfindungsgemäßen Anwendung zeigt sich eine hervorragende Verträglichkeit. Bei bestimmungsgemäßer Einnahme kommt es zu keinerlei Unverträglichkeiten. Auch nach Verzehr größerer Mengen an Fruchtsaft kommt es nicht zu einer Windeldermatitis. So behandelt führt auch Diarrhöe nicht zu einer sonst leicht entstehenden Windeldermatitis. Auch die Behandlung einer bereits bestehenden Windeldermatitis wird erfindungsgemäß begünstigt. Normalerweise führt eine zusätzliche Behandlung mit einem Antibiotikum zu einer Verschlechterung des Krankheitszustandes; nach Behandlung mit Produkten im Sinne der Erfindung provozieren Antibiotika keine Windeldermatitis.at the application of the invention shows an excellent compatibility. When used as intended there are no incompatibilities. Even after eating larger quantities Fruit juice does not cause diaper dermatitis. So treated leads as well diarrhea not to an otherwise easily developing diaper dermatitis. Also the treatment of existing diaper dermatitis is favored according to the invention. Usually leads an additional Treatment with an antibiotic to worsening the Disease state; after treatment with products in the sense of In the invention, antibiotics do not provoke diaper dermatitis.
Schließlich ist zu beachten, dass einige Cobalamin-Derivate, wie Metylcobalamin und Desoxyadenosylcobalamin, lichtempfindlich sind und in wässrigem Milieu hydrolysieren, so das für derartige Produkte insb. der Einsatz in Tabletten und anderen wasserfreien Produkten in Frage kommt..Finally is Note that some cobalamin derivatives, such as metylcobalamin and deoxyadenosylcobalamin, are light-sensitive and aqueous Hydrolyze environment, so for Such products esp. The use in tablets and other anhydrous Products in question ..
Claims (11)
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE102005012060A DE102005012060A1 (en) | 2005-03-16 | 2005-03-16 | Oral product for the prevention and treatment of diaper dermatitis |
PCT/EP2006/002363 WO2006097286A2 (en) | 2005-03-16 | 2006-03-15 | Orally-administered product for the prevention and treatment of nappy rash |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE102005012060A DE102005012060A1 (en) | 2005-03-16 | 2005-03-16 | Oral product for the prevention and treatment of diaper dermatitis |
Publications (1)
Publication Number | Publication Date |
---|---|
DE102005012060A1 true DE102005012060A1 (en) | 2006-09-21 |
Family
ID=36933801
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE102005012060A Withdrawn DE102005012060A1 (en) | 2005-03-16 | 2005-03-16 | Oral product for the prevention and treatment of diaper dermatitis |
Country Status (2)
Country | Link |
---|---|
DE (1) | DE102005012060A1 (en) |
WO (1) | WO2006097286A2 (en) |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5397786A (en) * | 1993-01-08 | 1995-03-14 | Simone; Charles B. | Rehydration drink |
EP0960572A1 (en) * | 1998-05-12 | 1999-12-01 | N.V. Nutricia | Nutritional composition for the treatment of pressure ulcers |
DE69904257T2 (en) * | 1999-01-20 | 2003-04-17 | Nutricia Nv | infant formula |
US20090186127A1 (en) * | 2004-12-15 | 2009-07-23 | Krumhar Kim C | Energy drink compositions |
-
2005
- 2005-03-16 DE DE102005012060A patent/DE102005012060A1/en not_active Withdrawn
-
2006
- 2006-03-15 WO PCT/EP2006/002363 patent/WO2006097286A2/en not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
WO2006097286A2 (en) | 2006-09-21 |
WO2006097286A3 (en) | 2007-05-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP2708147A1 (en) | Methods for increasing brain functionality using 2-fucosyl-lactose | |
DE202013002760U1 (en) | Dietary supplement for medication-oriented supplementation | |
DE60104853T2 (en) | Compositions comprising folic acid and zinc to improve sperm quality | |
WO2001084962A2 (en) | Compositions containing folic acid and reduced folate | |
EP2648807B1 (en) | Combination preparation for improving female fertility | |
EP1781330B1 (en) | Compositions containing a capillary active system with application-related differentiability, and the use thereof | |
DE102005011029A1 (en) | Composition for peroral application with controlled release of active substances | |
DE102005012060A1 (en) | Oral product for the prevention and treatment of diaper dermatitis | |
DE3316726A1 (en) | Therapeutically active mixture | |
DE202007008818U1 (en) | Composition for the treatment of infections | |
DE102006030037A1 (en) | Oral product, useful for preventing and treating seborrheic dermatitis, comprises cobalamin and/or betaines | |
EP3090638B1 (en) | Nutritional supplement to treat signs of vitamin d3 deficiency | |
DE3400276A1 (en) | Use of CDP-choline for the treatment of neurological disturbances | |
DE20320101U1 (en) | Micronutrient combination product suitable for a supplementary balanced diet for age-related macular degeneration | |
EP1437051B1 (en) | Ocuvite Lutein | |
DE60020888T2 (en) | EXTRACTS FROM HERBS FOR THE TREATMENT OF COGNITIVE DISTURBANCES DUE TO ESTROGEN LOSS | |
DE202004010212U1 (en) | Lutein-containing composition | |
EP1295601A1 (en) | Pharmaceutical composition based on a non-steroid anti-inflammatory agent | |
EP2259789A2 (en) | Pharmaceutical kit consisting of an oil-in-water emulsion and a solid composition | |
DE202023001658U1 (en) | Composition to improve sleep quality | |
Adelmann et al. | Neurologisch-neurochirurgische Krankheitsbilder | |
DE102005001645A1 (en) | Topical product for the prevention and treatment of diaper dermatitis | |
DE3441502A1 (en) | Pharmaceutical preparation for the prophylaxis of calcium oxalate stones | |
DE2033677A1 (en) | drug | |
AT13410U1 (en) | Use of a ubiquinone component and a combined preparation to improve female fertility |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8139 | Disposal/non-payment of the annual fee |